Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00334646 · ClinicalTrials.gov registry record · Phase 1
Cyclophosphamide Drug Interaction Study In Cancer Patients
A Phase 1 study, sponsored by GlaxoSmithKline.
- Terminated
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
NCT00334646: Clinical Trial Phase 1 study, sponsored by GlaxoSmithKline.
NCT00334646 is a Phase 1 study that was terminated before completion, run by GlaxoSmithKline. The registered enrollment target is 25 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (58% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00334646, a Phase 1 study, was terminated before completion, sponsored by GlaxoSmithKline.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
Study Summary
This study is designed to evaluate the potential pharmacokinetic interaction between oral GW679769 and IV (intravenous) cyclophosphamide when administered to cancer patients.
Interventions
- DRUG Oral GW679769
- DRUG IV Cyclophosphamide 500-700mg/m2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2005-08-10 |
| Est. Completion | 2009-10-14 |
| Phase | Phase 1 |
Why NCT00334646 stopped before completion
NCT00334646 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (58% lower).
The record links to 0 conditions, and to 2 interventions - of which Oral GW679769 is the first listed.
NCT00334646 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00334646 about?
NCT00334646 is a clinical study titled "Cyclophosphamide Drug Interaction Study In Cancer Patients". This study is designed to evaluate the potential pharmacokinetic interaction between oral GW679769 and IV (intravenous) cyclophosphamide when administered to cancer patients.
What is the current status of trial NCT00334646?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2005-08-10. Estimated completion is 2009-10-14.
What interventions are being tested in trial NCT00334646?
The interventions under investigation include: Oral GW679769 (DRUG), IV Cyclophosphamide 500-700mg/m2 (DRUG).
Who is sponsoring clinical trial NCT00334646?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00334646's enrollment target sits among peer trials
25 1495th of 2000 higher than 481 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI